Since PLD2 has been reported to promote the EGF receptor (EGFR) endocytosis through the activation of the Dynamin GTPase39, PLD2 might inhibit the EGF/EGFR circuit among tumor cells and stromal cells by limiting cell surface EGFR of stromal cells. The gene discussed is EGFR; the disease is neoplasm.